50 employees
Spyryx Biosciences develops a next-generation therapeutics for obstructive lung diseases.
2013
$18M
from 2 investors over 2 rounds
Spyryx Biosciences raised $18M on May 7, 2015
Investors: 5AM Ventures and Canaan